Get the Stockscreener App
0.7579
0.41%
-0.0031
Nautilus Biotechnology Inc stock is traded at $0.7579, with a volume of 79,425.
It is down -0.41% in the last 24 hours and down -4.47% over the past month.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
See More
Previous Close:
$0.761
Open:
$0.768
24h Volume:
79,425
Relative Volume:
0.27
Market Cap:
$95.61M
Revenue:
-
Net Income/Loss:
$-70.78M
P/E Ratio:
-1.3534
EPS:
-0.56
Net Cash Flow:
$-61.27M
1W Performance:
+4.52%
1M Performance:
-4.47%
6M Performance:
-60.53%
1Y Performance:
-73.68%
1-Day Range:
$0.75
$0.7856
1-Week Range:
$0.7205
$0.7856
52-Week Range:
$0.66
$3.09
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Name
Nautilus Biotechnology Inc
Sector
Industry
Phone
206-333-2001
Address
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
0.7579 | 96.00M | 0 | -70.78M | -61.27M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-02-21 | Initiated | Cowen | Outperform |
| Aug-04-21 | Initiated | Goldman | Neutral |
| Jul-13-21 | Initiated | Jefferies | Buy |
View All
Nautilus Biotechnology Inc Stock (NAUT) Latest News
Why Nautilus Biotechnology Inc. stock attracts strong analyst attention2x Return Forecast - Newser
Nautilus Biotechnology (NAUT) to Release Earnings on Thursday - Defense World
Is Nautilus Biotechnology Inc. a good long term investmentTremendous gains - Autocar Professional
What analysts say about Nautilus Biotechnology Inc. stockMarket-beating performance - jammulinksnews.com
Nautilus Biotechnology Inc. Stock Analysis and ForecastGame-changing capital returns - jammulinksnews.com
What makes Nautilus Biotechnology Inc. stock price move sharplyProfessional Stock Screener - Newser
What drives Nautilus Biotechnology Inc. stock priceFree Capital Growth Strategies - jammulinksnews.com
How Nautilus Biotechnology Inc. stock performs during market volatilityWeekly Big Movers - Newser
Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025 - 富途牛牛
What analysts say about Digital Ally Inc. stockSuperior risk-adjusted returns - Jammu Links News
Best Stocks for Conservative Investors in India Expert Long Term StocksExplosive capital appreciation - Jammu Links News
Macro Trends and Their Impact on Visaka Industries Limited (509055)Tremendous wealth creation - Jammu Links News
What makes Stagwell Inc. stock price move sharplyHigh Reward Swing Trades - Newser
Why HLXCP stock attracts strong analyst attentionOptimized Return Investment Picks - Newser
Why TSHA stock attracts strong analyst attentionWeekly Big Movers - Newser
Why Veris Residential Inc. stock attracts strong analyst attentionExplosive Growth Potential - Newser
Nautilus Biotechnology's Q2 2025: Can Proteomics Innovation Drive the Next Phase of Growth? - AInvest
Nautilus Biotechnology, Inc. to Report Second Quarter 2025 Financial Results and Host Webcast Conference Call - Nasdaq
What makes L.B. Foster Company stock price move sharplyDaily Swing Candidates - Newser
How ARAY stock performs during market volatilityFree Access to Community - Newser
Why GGAL stock attracts strong analyst attentionRisk Aware High Growth Picks - Newser
hpepe(hero pepe) price forecastProven Win Setups - Newser
Nautilus Biotechnology (NASDAQ:NAUT) Trading Down 7.5% – Should You Sell? - Defense World
The Next Generation of Proteome Analysis - the-scientist.com
Insiders of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) have had a great week after last week's US$12m gain and they haven't stopped buying - Yahoo Finance
EDGE(dadi) Price TodaySecure Your Capital Strategy - newser.com
Millennium Management LLC Purchases Shares of 37,704 Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Millennium Management LLC Has $171,000 Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
26,324 Shares in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Purchased by Squarepoint Ops LLC - Defense World
Home Product Center Public (OTCMKTS:HPCRF) Trading Up 20.5% – Should You Buy? - Defense World
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Shares Bought by Jane Street Group LLC - Defense World
Citadel Advisors LLC Raises Holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Tenpoint Therapeutics Ltd. Appoints Melissa Epperly as Chief Financial Officer - Business Wire
Northern Trust Corp Sells 32,695 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Nautilus Biotechnology Inc Stock (NAUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nautilus Biotechnology Inc Stock (NAUT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mallick Parag | Chief Scientist |
May 08 '25 |
Buy |
0.73 |
12,000 |
8,788 |
20,491,892 |
| Mallick Parag | Chief Scientist |
May 12 '25 |
Buy |
0.73 |
1,500 |
1,098 |
20,493,392 |
| Patel Sujal M | CEO, President, and Secretary |
Mar 19 '25 |
Buy |
0.99 |
53,300 |
53,028 |
10,117,788 |
| Patel Sujal M | CEO, President, and Secretary |
Mar 20 '25 |
Buy |
1.00 |
23,933 |
23,890 |
10,141,721 |
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):